2
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neoplasms
5
Polycythemia Vera
4
Lung Neoplasms
4
Ovarian Neoplasms
3
Myeloproliferative Disorders
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Lymphoma
2
Head and Neck Neoplasms
2
Carcinoma, Squamous Cell
2
Brain Neoplasms
2
Adenocarcinoma
2
Urticaria
1
Tuberous Sclerosis
1
Thymic aplasia
1
Thrombosis
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking
1
Small Cell Lung Carcinoma
1
Severe Combined Immunodeficiency
1
Sarcoma
1
Salivary Gland Neoplasms
1
Renal Insufficiency, Chronic
1
Rectal Neoplasms
1
Primary Dysautonomias
1
Polycythemia
1
Polycystic Ovary Syndrome
1
Pancreatitis, Chronic
1
Interventions
lutetium Lu 177 dotatate
40
Everolimus
35
Magnetic Resonance Spectroscopy
15
lanreotide
14
gallium Ga 68 dotatate
13
Temozolomide
13
Octreotide
12
Nivolumab
12
pembrolizumab
11
Capecitabine
11
surufatinib
10
177Lu-octreotide, DOTA(0)-Tyr(3)-
10
cabozantinib
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
Sunitinib
8
Specimen Handling
7
Carboplatin
7
telotristat ethyl
6
pasireotide
6
amino-acid, glucose, and electrolyte solution
6
Somatostatin
6
Lutetium-177
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
Ipilimumab
5
Ga(III)-DOTATOC
5
Fluorodeoxyglucose F18
5
Etoposide
5
Cisplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Phlebotomy
×
Clear all
NCT03130205
2017-08-25
PROGRESS
Uppsala University
Unknown
30 enrolled